ClinicalTrials.Veeva

Menu
A

American Institute of Research | Innovative Clinical Research Institute

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Pembrolizumab
Lenalidomide
Tyrosine
Gemcitabine
Dexamethasone
MT-3724
Docetaxel
Idelalisib
Oxaliplatin
Atezolizumab

Parent organization

This site is a part of American Institute of Research

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

31 of 82 total trials

A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation

A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS G12C mutation to determine the maximum tolerated dose and recom...

Enrolling
Solid Tumor
Cancer of Pancreas
Drug: HBI-2438

This will be a Phase 1, multicenter, open-label trial to evaluate the safety, tolerability, PK and efficacy of ZN-A-1041 as a monotherapy or in combi...

Enrolling
Advanced Solid Tumors
HER2-positive Breast Cancer
Drug: ZN-A-1041 50mg BID
Drug: ZN-A-1041 200mg BID

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced sol...

Enrolling
HER2-positive Advanced Solid Tumor
Drug: Itraconazole
Drug: Ritonavir

The purpose of this study is to learn about the effects of a study medicine, WGI-0301 to find the best dose for treating solid tumors, and to see how...

Enrolling
Advanced Solid Tumors
Drug: WGI-0301

The purpose of this study is to compare the efficacy and safety of pirtobrutinib (LOXO-305; Arm A) compared to BR (Arm B) in patients with CLL/SLL wh...

Active, not recruiting
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Pirtobrutinib
Drug: Bendamustine

The purpose of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL. Participants...

Active, not recruiting
Leukemia, B-cell
Small Lymphocytic Lymphoma
Drug: Pirtobrutinib
Drug: Ibrutinib

This study was to assess the antitumor activity, safety, tolerability, and pharmacokinetics (PK) of the Mesenchymal-epithelial Transition Factor (MET...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Tepotinib
Drug: Osimertinib

The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of z...

Enrolling
DLBCL
Diffuse Large B-Cell Lymphoma
Drug: Bendamustine
Biological: Zilovertamab vedotin

The participants of this study would have relapsed/refractory follicular lymphoma.Follicular lymphoma is a type of blood cancer. It is referred to as...

Enrolling
Relapsed/Refractory Follicular Lymphoma
Follicular Lymphoma
Combination Product: Rituximab
Drug: Placebo oral tablet

The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexameth...

Enrolling
Relapsed or Refractory Multiple Myeloma
Drug: Mezigdomide
Drug: Dexamethasone

The main purpose of this study is to evaluate the efficacy of sapablursen in reducing the frequency of phlebotomy and in improving quality of life as...

Active, not recruiting
Phlebotomy Dependent Polycythemia Vera
Drug: sapablursen

The purpose of this study is to evaluate zilovertamab vedotin with respect to objective response rate and duration of response per Lugano Response Cr...

Active, not recruiting
Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Biological: MK-2140 (zilovertamab vedotin)

Hand-Foot Skin Reaction (HFSR) is a common adverse event induced by Vascular Endothelial Growth Receptor Inhibitor (VEGFRi) treatment in cancer patie...

Active, not recruiting
Hand-Foot Skin Reaction (HFSR)
Drug: Vehicle Ointment
Drug: OQL011

This study will treat patients with advanced NSCLC with EGFR or HER2 mutation who have progressed following prior therapy. This is the first time thi...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Sunvozertinib

This study will compare DS 8201a to standard treatment.Participants must have HER2 breast cancer that has been treated before.Their cancer:* cannot b...

Active, not recruiting
Breast Cancer
Drug: Trastuzumab
Drug: Trastuzumab deruxtecan

This study is designed to compare the anti-tumor activity as well as the safety and efficacy of DS-8201a versus T-DM1 in HER2-positive, unresectable...

Active, not recruiting
Breast Cancer
Drug: Trastuzumab deruxtecan (T-DXd)
Drug: Ado-trastuzumab emtansine (T-DM1)

The purpose of the study is to compare the efficacy and safety of Luspatercept vs epoetin alfa in the treatment of anemia in adults due to IPSS-R ver...

Enrolling
Myelodysplastic Syndromes
Biological: Epoetin Alfa
Biological: Luspatercept

The study is designed to assess whether glufosfamide provides additional survival benefit as compared to bolus 5-FU in patients with metastatic pancr...

Enrolling
Metastatic Pancreatic Adenocarcinoma
Drug: Fluorouracil
Drug: Glufosfamide

Disease progression is typical for patients with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC). Standard platin...

Active, not recruiting
Nonsquamous Non-small Cell Lung Cancer
EGFR L858R
Drug: Platinum-based chemotherapy
Drug: Patritumab Deruxtecan

This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with myelofibrosis (MF) who no longer bene...

Enrolling
Post-Polycythemia Vera MF (Post-PV-MF)
Primary Myelofibrosis (PMF)
Drug: Best Available Therapy (BAT)
Drug: KRT-232

Trial sponsors

Gilead Sciences logo
Daiichi Sankyo logo
Incyte logo
Celgene logo
Molecular Templates logo
Amgen logo
Bristol-Myers Squibb (BMS) logo
F
Kartos Therapeutics logo
Loxo Oncology logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems